Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the Kennedy Institute, part of NDORMS have repurposed the approved drug miglustat to successfully slow the progression of multiple myeloma.

Researchers at the Kennedy Institute, part of NDORMS have repurposed the approved drug miglustat to successfully slow the progression of multiple myeloma.

Multiple myeloma is the second most common blood cancer and there is no known cure for it. Patients suffering from the condition have debilitating pain caused by bone damage, show tiredness, and are prone to infections.

The condition leads to the accumulation of plasma cells, a type of white blood cell, in the bone marrow, interfering with the production of normal blood cells. In addition, myeloma cells promote the activity of osteoclasts – bone cells that destroy and remove bone tissue.

Whilst incurable, multiple myeloma is currently managed using either drugs that target the myeloma cells thus reducing the burden on the bone marrow or drugs which reduce the activity of the osteoclasts. Occasionally, treatment will involve a mix of different therapies and/or a bone marrow transplant.

The research led by Professor Nikki Horwood used a commercial drug developed by Oxford GlycoSciences for the treatment of Gaucher disease – miglustat – and showed it to act on both aspects of multiple myeloma, slowing disease progression and alleviating its symptoms. Whilst still not a definitive cure, miglustat has clear benefits over current therapies for myeloma and would keep disease at bay for the 5,000 people diagnosed with multiple myeloma each year in the UK

Professor Horwood said: "This research is an important step towards targeting myeloma bone disease on more than one front, the cancer cells themselves and the bone destroying cells, using only one drug, which is a fantastic improvement for patients. Miglustat is a commercial drug already available on the market thus translation into clinical practice could happen quicker.  We are continuing to investigate Miglustat, and related drugs, in multiple myeloma and this research provides the proof of principle platform we needed for clinical translation."

You can read the full paper here.

 

This work was supported by the Multiple Myeloma Research Foundation (AE, NH, AK), Leukaemia and Lymphoma Research (KX, AE, AC, ES, MH, AR, IR, DSA, NH and AK), Arthritis Research UK (NH, LD), Kennedy Institute Trustees (YV) and the Glycobiology Institute, University of Oxford (GT, RAD and TDB).

Image: Left - Control group shows holes straight through the bone (blue background). Right - in the group treated with miglustat these holes are almost completely absent.

Similar stories

Professor Sir Gordon Duff receives Honorary Senior Fellowship at NDORMS

Professor Sir Gordon Duff has been awarded an Honorary Senior Fellowship at NDORMS.

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Afsie Sabokbar wins Lifetime Achievement at Teaching Excellence Awards

Director of Graduate Studies Afsie Sabokbar wins Lifetime Achievement at 2021 Teaching Excellence Awards.

NDORMS staff recognised in the 2021 Teaching Excellence Awards

Director of Graduate Studies Afsie Sabokbar, Associate Professor Stephanie Dakin and Graduate Studies Officer Samuel Burnell were all winners in the Teaching Excellence Awards.

Five ways to take action for your bone health

On World Osteoporosis Day, the International Osteoporosis Foundation (IOF), the world’s largest non-governmental organisation in the bone field, urges action for osteoporosis and fracture prevention.